-
Je něco špatně v tomto záznamu ?
Context-dependent multifunctionality of galectin-1: a challenge for defining the lectin as therapeutic target
K. Smetana, S. André, H. Kaltner, J. Kopitz, HJ. Gabius,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
- MeSH
- biologický transport účinky léků MeSH
- buněčná adheze účinky léků MeSH
- cílená molekulární terapie MeSH
- galektin 1 antagonisté a inhibitory metabolismus MeSH
- galektiny antagonisté a inhibitory metabolismus MeSH
- glykokonjugáty metabolismus MeSH
- lidé MeSH
- nádorové proteiny antagonisté a inhibitory metabolismus MeSH
- nádory farmakoterapie prevence a kontrola MeSH
- proliferace buněk účinky léků MeSH
- protinádorové látky farmakologie terapeutické užití MeSH
- racionální návrh léčiv * MeSH
- signální transdukce účinky léků MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
INTRODUCTION: One route of translating the information encoded in the glycan chains of cellular glycoconjugates into physiological effects is via receptor (lectin) binding. A family of endogenous lectins, sharing folding, a distinct sequence signature and affinity for β-galactosides (thus termed galectins), does so effectively in a context-dependent manner. AREAS COVERED: An overview is given on the multifunctional nature of galectins, with emphasis on galectin-1. The broad range of functions includes vital processes such as adhesion via glycan bridging, glycoconjugate transport or triggering signaling relevant, for example, for growth regulation. Besides distinct glycoconjugates, this lectin can also interact with certain proteins so that it can target counterreceptors at all sites of location, that is, in the cytoplasm and/or nucleus, at both sides of the membrane or extracellularly. Approaches to strategically exploit galectin activities with therapeutic intentions are outlined. EXPERT OPINION: The wide versatility of sugar coding and the multifunctionality of galectin-1 explain why considering to turn the protein into a therapeutic target is an ambitious aim. Natural pathways shaped by physiologic master regulators (e.g., the tumor suppressor p16(INK4a)) are suggested to teach inspiring lessons as to how the lectin might be recruited to clinical service.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13031738
- 003
- CZ-PrNML
- 005
- 20131023103817.0
- 007
- ta
- 008
- 131002s2013 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1517/14728222.2013.750651 $2 doi
- 035 __
- $a (PubMed)23289445
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Smetana, Karel $u Institute of Anatomy, 1st Faculty of Medicine, Charles University, U Nemocnice 3, 128 00 Prague, Czech Republic.
- 245 10
- $a Context-dependent multifunctionality of galectin-1: a challenge for defining the lectin as therapeutic target / $c K. Smetana, S. André, H. Kaltner, J. Kopitz, HJ. Gabius,
- 520 9_
- $a INTRODUCTION: One route of translating the information encoded in the glycan chains of cellular glycoconjugates into physiological effects is via receptor (lectin) binding. A family of endogenous lectins, sharing folding, a distinct sequence signature and affinity for β-galactosides (thus termed galectins), does so effectively in a context-dependent manner. AREAS COVERED: An overview is given on the multifunctional nature of galectins, with emphasis on galectin-1. The broad range of functions includes vital processes such as adhesion via glycan bridging, glycoconjugate transport or triggering signaling relevant, for example, for growth regulation. Besides distinct glycoconjugates, this lectin can also interact with certain proteins so that it can target counterreceptors at all sites of location, that is, in the cytoplasm and/or nucleus, at both sides of the membrane or extracellularly. Approaches to strategically exploit galectin activities with therapeutic intentions are outlined. EXPERT OPINION: The wide versatility of sugar coding and the multifunctionality of galectin-1 explain why considering to turn the protein into a therapeutic target is an ambitious aim. Natural pathways shaped by physiologic master regulators (e.g., the tumor suppressor p16(INK4a)) are suggested to teach inspiring lessons as to how the lectin might be recruited to clinical service.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protinádorové látky $x farmakologie $x terapeutické užití $7 D000970
- 650 _2
- $a biologický transport $x účinky léků $7 D001692
- 650 _2
- $a buněčná adheze $x účinky léků $7 D002448
- 650 _2
- $a proliferace buněk $x účinky léků $7 D049109
- 650 12
- $a racionální návrh léčiv $7 D015195
- 650 _2
- $a galektin 1 $x antagonisté a inhibitory $x metabolismus $7 D037483
- 650 _2
- $a galektiny $x antagonisté a inhibitory $x metabolismus $7 D037161
- 650 _2
- $a glykokonjugáty $x metabolismus $7 D006001
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a cílená molekulární terapie $7 D058990
- 650 _2
- $a nádorové proteiny $x antagonisté a inhibitory $x metabolismus $7 D009363
- 650 _2
- $a nádory $x farmakoterapie $x prevence a kontrola $7 D009369
- 650 _2
- $a signální transdukce $x účinky léků $7 D015398
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a André, Sabine $u - $7 gn_A_00006374
- 700 1_
- $a Kaltner, Herbert $u -
- 700 1_
- $a Kopitz, Jürgen $u -
- 700 1_
- $a Gabius, Hans-Joachim $u -
- 773 0_
- $w MED00182172 $t Expert opinion on therapeutic targets $x 1744-7631 $g Roč. 17, č. 4 (2013), s. 379-92
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23289445 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20131002 $b ABA008
- 991 __
- $a 20131023104409 $b ABA008
- 999 __
- $a ok $b bmc $g 995825 $s 830183
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 17 $c 4 $d 379-92 $i 1744-7631 $m Expert opinion on therapeutic targets $n Expert Opin Ther Targets $x MED00182172
- LZP __
- $a Pubmed-20131002